Form 4: GeoVax Labs Director Jayne Morgan Reports Stock Option Grant Following Shareholder Approval

GeoVax Labs, Inc. Director Jayne Morgan has reported the acquisition of 10,000 stock options with an exercise price of $2.48, following shareholder approval of the company's 2025 Stock Incentive Plan.

Summary

• Jayne Morgan, a Director of GeoVax Labs, Inc. (GOVX), reported the acquisition of 10,000 stock options.
• The stock options have an exercise price of $2.48 per share.
• The options were initially granted on January 2, 2025, but became effective for SEC reporting purposes on June 5, 2025, upon stockholder approval of the GeoVax Labs, Inc. 2025 Stock Incentive Plan.
• These options will become exercisable on January 2, 2026, and are set to expire on January 2, 2035.
• Following this transaction, Ms. Morgan directly beneficially owns 10,000 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as it indicates a standard corporate governance action (director compensation) that aligns management interests with shareholders, following successful shareholder approval of an incentive plan. It does not contain any negative operational or financial news.

Positives

• The grant of stock options to Director Jayne Morgan aligns her interests with those of shareholders, incentivizing long-term performance.
• Shareholder approval of the 2025 Stock Incentive Plan indicates support for the company's compensation strategy and its ability to attract and retain talent.

Negatives

• No specific negative financial or operational information is disclosed in this Form 4 filing.

Risks

• The initial grant of the stock option was contingent upon stockholder approval of the GeoVax Labs, Inc. 2025 Stock Incentive Plan; however, this contingency has now been met as approval occurred on June 5, 2025.

Future Outlook

The stock options granted to Director Jayne Morgan will become exercisable on January 2, 2026, and will expire on January 2, 2035, providing a long-term incentive for her continued contribution to the company's performance.

Management Comments

• "This stock option was granted on January 2, 2025, with the exercise price set based on the closing price of the underlying common stock as of that date. The stock option was granted contingent upon stockholder approval of the GeoVax Labs, Inc. 2025 Stock Incentive Plan. Such approval occurred on June 5, 2025, so that is the date upon which the stock option is deemed granted pursuant to SEC reporting guidance."

Industry Context

The granting of stock options to directors is a common practice across various industries, including biotechnology and pharmaceuticals, serving as a key component of executive and board compensation. This practice aims to align the interests of leadership with long-term shareholder value creation, reflecting standard corporate governance and incentive structures.

Comparison to Industry Standards

• NA

Corporate Governance

Related Party Transactions

• The grant of 10,000 stock options to Jayne Morgan, a Director of GeoVax Labs, Inc., constitutes a related party transaction as part of her compensation package.

Stakeholder Impact

• **Shareholders**: The grant of stock options to a director aims to align management's long-term interests with shareholder value creation, potentially leading to improved company performance.
• **Employees**: The approval of the 2025 Stock Incentive Plan suggests a broader framework for equity compensation, which could benefit other employees in the future, enhancing retention and motivation.

Next Steps

• The stock options granted to Jayne Morgan will become exercisable on January 2, 2026.

Key Dates

Keywords

GeoVax Labs, GOVX, Stock Option, Director Compensation, SEC Form 4, Insider Transaction, Equity Incentive Plan, Corporate Governance